Tevogen Bio Finalizes 100M Share Incentive Plan & Reverse Split Approval, Paving Way for Significant Dilution

summarizeSummary

Tevogen Bio Holdings Inc. filed a prospectus supplement to enable the issuance of 100 million additional shares under its incentive plan and confirmed shareholder approval for a reverse stock split, signaling significant potential dilution and a move to address its low stock price.

check_boxKey Events

• Shareholder Approvals Confirmed

  Shareholders approved a 100 million share increase to the 2024 Omnibus Incentive Plan and authorized the Board to effect a reverse stock split at a ratio between 1:25 and 1:85.

• Significant Dilution Potential

  The 100 million additional shares now available for issuance represent approximately 50% of the company's currently outstanding shares, enabling substantial future dilution.

• Reverse Stock Split Authorized

  The Board now has the discretion to implement a reverse stock split, a measure typically used to increase share price and meet exchange listing requirements.

auto_awesomeAnalysis

This 424B3 prospectus supplement confirms the shareholder approval, previously reported in the February 25, 2026 8-K, for a substantial increase in the company's equity incentive plan by 100 million shares. This authorization makes these shares available for issuance, representing a potential dilution of nearly 50% of the current outstanding shares, which is a significant impact on existing shareholder value. Concurrently, the approval of a reverse stock split (with a ratio between 1:25 and 1:85) indicates the company is taking steps to address its low stock price, likely to maintain Nasdaq listing compliance. Investors should be aware of the substantial dilutive potential and the implications of the reverse stock split on share price and liquidity.